ImmuPharma PLC

NEW
FRA:25I (UK)  
€ 0.037 (0%) Jul 10
At Loss
P/B:
40.45
Market Cap:
€ 29.25M ($ 33.40M)
Enterprise V:
€ 27.69M ($ 31.61M)
Volume:
0
Avg Vol (2M):
35.81K
Trade In:

Business Description

Description
ImmuPharma PLC focuses on the research, development, and commercialisation of pioneering and novel drugs in specialist therapeutic areas within the pharmaceutical industry. The company's pipeline products are P140, CDx, Kapiglucagon, BioAMB, and BioCIN.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
No Debt
Equity-to-Asset
0.37
Piotroski F-Score
2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
62.8
9-Day RSI
58.65
14-Day RSI
55.52
3-1 Month Momentum %
-14.47
6-1 Month Momentum %
-48.41
12-1 Month Momentum %
225

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
1.52
Quick Ratio
1.52
Cash Ratio
1.13

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-14.7
Shareholder Yield %
-5.02

Profitability Rank

Name Current Vs Industry Vs History
ROE %
-1127.65
ROA %
-122.24
ROIC %
-315.14
3-Year ROIIC %
-43.05
ROC (Joel Greenblatt) %
-2937.56
ROCE %
-1349.69

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio
40.45
EV-to-EBIT
-11.04
EV-to-EBITDA
-11.22
EV-to-FCF
-10.07
Price-to-GF-Value
1.25
Earnings Yield (Greenblatt) %
-9.06
FCF Yield %
-9.4

Financials (Next Earnings Date:2026-08-06 Est.)

FRA:25I's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

ImmuPharma PLC Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.004
Beta -46.8723
3-Year Sharpe Ratio 0.85
3-Year Sortino Ratio 26.09
Volatility % 536.36
14-Day RSI 55.52
14-Day ATR (€) 0.004826
20-Day SMA (€) 0.030575
12-1 Month Momentum % 225
52-Week Range (€) 0.0005 - 0.218
Shares Outstanding (Mil) 623.91

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

ImmuPharma PLC Filings

Filing Date Document Date Form
No Filing Data

ImmuPharma PLC Stock Events

Financials Calendars
Event Date Price (€)
Second quarter earnings results for 2026 2026-08-06 In 25 days
General meeting for 2025 2026-06-25 10:00 0.03 (+0.00%)
Annual report for 2025 2026-06-02 0.03 (+0.00%)
Fourth quarter earnings results for 2025 2026-05-27 0.03 (+0.00%)
Second quarter earnings results for 2025 2025-08-06 0.02 (+325.00%)
General meeting for 2024 2025-06-12 11:00 0.02 (+0.00%)
Annual report for 2024 2025-05-19 0.02 (-19.05%)
Fourth quarter earnings results for 2024 2025-05-19 0.02 (-19.05%)
Second quarter earnings results for 2024 2024-09-09 0.01 (+0.00%)
Show
Entries

ImmuPharma PLC Frequently Asked Questions

What is ImmuPharma PLC(FRA:25I)'s stock price today?
The current price of FRA:25I is €0.04. The 52 week high of FRA:25I is €0.22 and 52 week low is €0.00.
When is next earnings date of ImmuPharma PLC(FRA:25I)?
The next earnings date of ImmuPharma PLC(FRA:25I) is 2026-08-06 Est..
Does ImmuPharma PLC(FRA:25I) pay dividends? If so, how much?
ImmuPharma PLC(FRA:25I) does not pay dividend.

Press Release

Subject Date
No Press Release

Articles on ImmuPharma PLC

No articles.